# A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer

> **NCT04521764** · PHASE1 · RECRUITING · sponsor: **Mayo Clinic** · enrollment: 54 (estimated)

## Conditions studied

- Anatomic Stage IV Breast Cancer AJCC v8
- Invasive Breast Carcinoma
- Metastatic Breast Adenocarcinoma
- Recurrent Breast Carcinoma
- Stage IV Breast Cancer AJCC v6 and v7

## Interventions

- **BIOLOGICAL:** Oncolytic Measles Virus Encoding Helicobacter pylori Neutrophil-activating Protein
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Magnetic Resonance Imaging
- **PROCEDURE:** Biopsy
- **PROCEDURE:** Biospecimen Collection

## Key facts

- **NCT ID:** NCT04521764
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-09-23
- **Primary completion:** 2027-08-15
- **Final completion:** 2027-08-15
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2026-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04521764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04521764, "A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-20 from https://api.ai-analytics.org/clinical/NCT04521764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*